Brian Goff Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

Brian Goff is Chief Executive Officer of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 143,103 shares of AGIO, which is worth approximately $6.25 Million. The most recent transaction as insider was on Dec 30, 2025, when has been sold 18,703 shares (Common Stock) at a price of $27.09 per share, resulting in proceeds of $506,664. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 143K

15.85% 3M change

81.62% 12M change

Total Value Held $6.25 Million

Brian Goff Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 30 2025	SELL Open market or private sale	$506,664 $27.09 p/Share	18,703 Reduced 11.56%	143,103 Common Stock
Dec 30 2025	BUY Exercise of conversion of derivative security	-	38,278 Added 20.4%	149,333 Common Stock
Aug 08 2025	SELL Open market or private sale	$406,486 $36.67 p/Share	11,085 Reduced 8.23%	123,528 Common Stock
Aug 08 2025	BUY Exercise of conversion of derivative security	-	22,691 Added 14.42%	134,613 Common Stock
Jun 24 2025	SELL Open market or private sale	$627,198 $33.54 p/Share	18,700 Reduced 14.32%	111,922 Common Stock
Jun 24 2025	BUY Exercise of conversion of derivative security	-	38,277 Added 24.47%	118,151 Common Stock
Mar 03 2025	SELL Open market or private sale	$460,136 $35.54 p/Share	12,947 Reduced 12.3%	92,345 Common Stock

Mar 01 2025	BUY Exercise of conversion of derivative security	-	26,500 Added 20.76%	101,139 Common Stock
Aug 08 2024	SELL Open market or private sale	$474,140 $42.75 p/Share	11,091 Reduced 12.34%	78,792 Common Stock
Aug 08 2024	BUY Exercise of conversion of derivative security	-	22,691 Added 20.16%	89,883 Common Stock
Jun 05 2024	SELL Open market or private sale	$591,696 $48.84 p/Share	12,115 Reduced 15.28%	67,192 Common Stock
Jun 05 2024	BUY Exercise of conversion of derivative security	-	25,527 Added 24.35%	79,307 Common Stock
Mar 05 2024	SELL Open market or private sale	$135,360 $32.57 p/Share	4,156 Reduced 7.17%	53,780 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	8,500 Added 12.79%	57,936 Common Stock
Jan 24 2024	SELL Open market or private sale	$165,221 $21.64 p/Share	7,635 Reduced 13.38%	49,436 Common Stock
Jan 20 2024	BUY Exercise of conversion of derivative security	-	17,018 Added 22.97%	57,071 Common Stock
Jan 09 2024	SELL Open market or private sale	$277,397 $22.99 p/Share	12,066 Reduced 23.15%	40,053 Common Stock
Jan 05 2024	BUY Exercise of conversion of derivative security	-	25,527 Added 32.88%	52,119 Common Stock
Aug 08 2023	SELL Open market or private sale	$259,335 $25.48 p/Share	10,178 Reduced 27.68%	26,592 Common Stock
Aug 08 2023	BUY Exercise of conversion of derivative security	-	22,691 Added 38.16%	36,770 Common Stock
Jun 30 2023	SELL Open market or private sale	$324,693 $28.36 p/Share	11,449 Reduced 44.85%	14,079 Common Stock
Jun 28 2023	BUY Exercise of conversion of derivative security	-	25,528 Added 50.0%	25,528 Common Stock

Also insider at

NTLA

Intellia Therapeutics, Inc. Healthcare

ALXN

ALEXION PHARMACEUTICALS, INC.

EVP & Chief Commercial Officer

Brian Goff

Chief Executive Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Value

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

Operation

Value

Type

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO

Account